Fitch: JNJ's Diagnostics Divestiture Makes Strategic Sense

CHICAGO & NEW YORK--()--A proposed transaction between Johnson & Johnson (JNJ) and The Carlyle Group is viewed as strategically sound, according to Fitch Ratings. We believe the margins and long-term growth opportunities for this business had been lower versus those for the total firm. While the sale will incrementally improve JNJ's total profitability, it should only modestly reduce the diversification of its portfolio, given that the diagnostics business accounts for roughly only 2.7% of total firm sales.

JNJ this week announced that The Carlyle Group has offered to buy its Ortho-Clinical Diagnostics business for $4.15 billion in cash. The transaction is expected to close mid-year 2014, assuming various regulatory approvals and stakeholder agreements. JNJ had previously announced that it was evaluating strategic options for the business.

JNJ had roughly $25.2 billion in cash and marketable securities and a net cash position of $10.1 billion at Sept. 30, 2013. In addition, leverage (total debt/EBITDA) for the latest 12-month period was 0.65x. As such, Fitch believes the company has solid liquidity and ample discretionary headroom regarding how it uses the anticipated proceeds from the transaction.

Fitch believes JNJ, as well as other large branded pharmaceutical firms, will continue to strategically evaluate their portfolios. We anticipate that other potential divestitures in the sector will be generally neutral to ratings, as the possible reduction in portfolio diversification will be mitigated by the prospects for improved growth and profitability.

Fitch's issuer default rating for JNJ is 'AAA' with a Stable Rating Outlook.

Additional information is available on www.fitchratings.com.

The above article originally appeared as a post on the Fitch Wire credit market commentary page. The original article, which may include hyperlinks to companies and current ratings, can be accessed at www.fitchratings.com. All opinions expressed are those of Fitch Ratings.

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

Contacts

Fitch Ratings, Inc.
Robert Kirby, CFA, +1 312-368-3147
Director
Corporates
Fitch Ratings, Inc.
70 W. Madison
Chicago, IL
or
Kellie Geressy-Nilsen, +1 212-908-9123
Senior Director
Fitch Wire
One State Street Plaza
New York, NY
or
Media Relations
Brian Bertsch, +1 212-908-0549
brian.bertsch@fitchratings.com

Sharing

Contacts

Fitch Ratings, Inc.
Robert Kirby, CFA, +1 312-368-3147
Director
Corporates
Fitch Ratings, Inc.
70 W. Madison
Chicago, IL
or
Kellie Geressy-Nilsen, +1 212-908-9123
Senior Director
Fitch Wire
One State Street Plaza
New York, NY
or
Media Relations
Brian Bertsch, +1 212-908-0549
brian.bertsch@fitchratings.com